Medtronic (MDT) closed the latest trading day at $90.07, indicating a +0.92% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.41%.

A former Medtronic consultant received an 18-month prison sentence this week for his role in a scheme linked to the $1.6 billion acquisition of an Israeli medical device company in 2018.

A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...

Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to ...

Medtronic (MDT) closed the latest trading day at $90.60, indicating a +0.01% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, ...

(Courtesy of Medtronic) At the time, pacemakers were “crude devices,” with wires coming out of the person’s body and “they ..

The new director overseeing medical devices will confront criticisms about hasty approvals as she ushers in revolutionary ...

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. We look at what the results mean for ...

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation ...

Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.